The historical paradigm where Western laboratories exclusively dictated the rhythm of pharmaceutical progress is rapidly disintegrating as China establishes itself as a primary source of high-value drug candidates. For many decades, the global healthcare sector followed a remarkably predictable
The emergence of chimeric antigen receptor T-cell therapy has revolutionized the oncological landscape by providing a potent "living drug" that can hunt and destroy malignant cells, yet nearly half of all patients still experience clinical relapses that threaten the long-term viability of this
Ivan Kairatov joins us today to share his deep expertise in biopharmaceutical innovation, particularly within the specialized field of rare kidney diseases. With a career rooted in the research and development of transformative therapies, Kairatov offers a unique perspective on the shifting
The journey of a life-saving injectable molecule often begins with a deceptive sense of simplicity on a laboratory bench, only to face an unforgiving reality when moved toward large-scale clinical manufacturing. While the ambition to reach in-human trials quickly is a common driver for drug owners,
Healthcare providers have long grappled with the delicate balance between achieving the crystal-clear diagnostic images required for life-saving interventions and minimizing the chemical burden placed on the human body during repeated medical procedures. The recent FDA approval of Ambelvist, known
Ivan Kairatov is a leading voice in biopharmaceutical innovation, bringing years of experience in metabolic research and the development of disruptive medical technologies. In this discussion, we explore the recent landmark approval of an oral semaglutide tablet by the UK’s Medicines and Healthcare
